Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs — clopidogrel and aspirin — lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks.